Evotec AG (NASDAQ:EVO – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $1.89 and last traded at $1.89, with a volume of 12713 shares. The stock had previously closed at $1.93.
Analyst Ratings Changes
A number of research analysts recently weighed in on EVO shares. Berenberg Bank lowered shares of Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research report on Tuesday, July 21st. HC Wainwright decreased their price objective on shares of Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, July 15th. Wall Street Zen cut shares of Evotec from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a report on Wednesday, July 15th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $3.00.
Read Our Latest Stock Analysis on Evotec
Evotec Stock Performance
Hedge Funds Weigh In On Evotec
Institutional investors and hedge funds have recently bought and sold shares of the company. Apollon Wealth Management LLC bought a new stake in shares of Evotec in the first quarter valued at $28,000. Marshall Wace LLP purchased a new stake in Evotec during the fourth quarter valued at about $40,000. SmartHarvest Portfolios LLC purchased a new stake in Evotec during the first quarter valued at about $44,000. BNP Paribas Financial Markets boosted its position in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares in the last quarter. 5.81% of the stock is owned by institutional investors.
About Evotec
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.
Further Reading
- Five stocks we like better than Evotec
- Marzetti Stock Confirms Reversal on Earnings Strength, Dividend Growth
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
